J&J Beats Q3 Earnings Expectations After Dozens of Prescription Drug Price Hikes in 2022

This week, Johnson & Johnson kicked off third-quarter earnings reports for the pharmaceutical industry. The Big Pharma giant once again bested Wall Street analysts’ expectations, driven by strong sales in the company’s pharmaceutical division, after the company raised prices on dozens of prescription drugs earlier this year.

Despite an escalating crisis of affordability, the Big Pharma giant has continued to engage in a business-as-usual approach to increasing prices on the brand name drugs in its portfolio.

Stay tuned as we continue to monitor earnings calls from Big Pharma for Q3 of 2022 over the next few weeks.

Learn more about solutions to lower prescription drug prices and hold Big Pharma accountable HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.